Agendia Presents Data Demonstrating Value of MammaPrint, BluePrint across Breast Cancer Populations
At the 2017 San Antonio Breast Cancer Symposium, Agendia presented extensive new data highlighting the value of its MammaPrint 70-gene breast cancer risk-of-recurrence test and BluePrint breast cancer molecular subtyping test.
Read More